Financial
Latest full-year results from official filings.
FY2025 revenue €7.52bn (+7.0%); net margin 5.3%; net income €402.0m.
Net profit more than doubled; EBIT and leverage not captured.
- Official results release · Grifols · 31 Dec 2025
Grifols: risk summary
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Adverse media
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Aug 2025: Spain's securities regulator CNMV fined Grifols and several executives about €1.36m in total for inaccurate information in its 2021–2023 accounts and misleading performance measures, following short-seller Gotham City Research's 2024 allegations.
- Spanish regulator fines Grifols almost €1.4m following Gotham allegations · Catalan News · 7 Aug 2025
Cyber & information governance
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches or cyber incidents involving Grifols found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Recalls, safety notices, regulator action and clinical safety concerns.
Nov 2025: Grifols Therapeutics recalled one lot of Gammaked immune globulin in the US after a higher rate of allergic and hypersensitivity reactions, including a small number of medically significant cases. No diagnostics-specific actions found.
- Gammaked Recalled · Express Scripts · 17 Nov 2025
Contract performance
Contract delivery, go-lives, terminations and disputes.
Jun 2025: NHS Blood and Transplant directly awarded Grifols UK a £131k (ex VAT) contract to supply 500ml cell media bottles. No disputes or terminations found in HSH's search of the last 24 months.
- Contract 2. Supply of Cell Media Bottles · Find a Tender Service · 16 Jun 2025